Real world patient outcomes with immune checkpoint inhibitors in metastatic melanoma match the survival outcomes and toxicities seen in randomised controlled trials, UK experience shows. The findings come from a review of NHS cancer databases for more than 2300 patients with melanoma treated with pembrolizumab, ipilimumab, nivolumab, and combinations of ipilimumab and nivolumab between 2014 ...
Melanoma real world outcomes with checkpoint inhibitors are similar to RCTs
By Michael Woodhead
27 Feb 2020